Novel Piperazine Derivatives as Potent Antihistamine, Anti-Inflammatory, and Anticancer Agents, their Synthesis and Characterization. 2024

Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
M.S. Ramaiah University of Applied Sciences, Karnataka, 560058, Bangalore, India.

BACKGROUND In this study, a series of novel piperazine derivatives were synthesised with high-to-good yields, and their structural analogies were confirmed using FTIR, 1H-NMR, and LC-MS techniques. METHODS The synthesised compounds were evaluated for antioxidant and antimicrobial activities. Among the four synthesised piperazine derivatives, compound PD-2 exhibited relatively good antioxidant activity, with an IC50 value of 2.396 μg/mL, while the other three derivatives showed moderate to low antioxidant activity. Furthermore, compound PD-2 displayed antimicrobial activity against Pseudomonas aeruginosa, a gram-negative bacterium, and Candida albicans, a fungus. However, all four compounds showed strong resistance against grampositive bacteria, Staphylococcus aureus. RESULTS Additionally, compound PD-1 exhibited significant antihistamine activity, eliciting an 18.22% reduction in histamine levels. Both PD-1 and PD-2 demonstrated noteworthy anti-inflammatory activity in a dosedependent manner (5-10μM), leading to the inhibition of nitrite production up to 39.42% and 33.7% at higher concentrations (10 μM) and inhibition of tumour necrosis factor-alpha (TNF-α) generation up to 56.97% and 44.73% at 10 μM, respectively. Additionally, both novel molecules PD-1 and PD-2 effectively restrained the growth of HepG2 cells in a manner that is dependent on the dosage up to 55.44% and 90.45% at the highest concentrations (100 μg/mL), respectively. CONCLUSIONS These findings substantiate the rationale for further investigation into the novel series of persuasive piperazine analogues as potential agents with anti-inflammatory, antihistamine and anticancer properties.

UI MeSH Term Description Entries

Related Publications

Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
January 2023, Natural product research,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
June 2015, Bioorganic & medicinal chemistry letters,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
January 2016, Journal of enzyme inhibition and medicinal chemistry,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
October 2012, Bioorganic & medicinal chemistry letters,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
March 2013, Molecules (Basel, Switzerland),
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
August 2010, Bioorganic & medicinal chemistry,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
January 2017, Anti-cancer agents in medicinal chemistry,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
September 2013, Journal of Asian natural products research,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
June 2023, International journal of molecular sciences,
Ameer Mohammed R, and Kannika K Shetty, and Lairikyengbam Deepti Roy, and Jyotsna Kumar
December 2014, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!